Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.97 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173263 | 0.83 | MEN1 (0.68) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL11704564 | 0.82 | MEN1 (0.68) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL11702648 | 0.82 | MEN1 (0.68) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL11704369 | 0.81 | MEN1 (0.66) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL11701921 | 0.80 | MEN1 (0.74) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL13286054 | 0.79 | MEN1 (0.64) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL419725 | 0.78 | MEN1 (0.63) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL11701818 | 0.78 | MEN1 (0.62) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL13609156 | 0.78 | MEN1 (0.62) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL19148510 | 0.78 | MEN1 (0.62) | MEN1KMT2ALMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | MEN1 1731/4885KMT2A 3769/4885LMNA 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.